
Opinion|Videos|July 18, 2024
Incorporating ctDNA-Based MRD Testing and Study Findings Into Clinical Practice
Medical experts examine how recent data on circulating tumor DNA-based minimal residual disease testing may impact the clinical management and treatment of colorectal cancer.
Advertisement
Episodes in this series

- Please discuss the clinical implications of these recent data for the utility of ctDNA-based MRD testing in CRC treatment and management
- Are any of these findings practice-changing?
- Are you routinely testing patients after surgery and after adjuvant therapy on the basis of these data?
- What are some barriers to enrollment surrounding MRD testing in CRC for ongoing adjuvant studies (like CIRCULATE)?
- Are patients wanting to escalate or de-escalate treatment?
- How are patients reacting to study testing?
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Matching Neoadjuvant Therapy to Tumor Genomics in High-Risk Prostate Cancer
2
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
3
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
4
Second-Line Options and Selecting Ipilimumab Plus Nivolumab in RCC
5

